Vector and method for treating bietti's crystalline dystrophy
The present application relates to a vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2. The vector described herein has a good expression effect, high expression speed, and more stable expression intensity. The present application also provides cells, pharmaceutical compositions, and kits comprising the vector, and methods for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.
1. A vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2; wherein the vector comprises the entire nucleotide sequence set forth in SEQ ID NO: 11; and wherein the vector is a recombinant AAV2/8 vector.
2. The vector according to claim 1 , wherein the vector further comprises a polyadenylation (PolyA) signal site located at 3′ end of the polynucleotide encoding CYP4V2, wherein the polyadenylation (PolyA) signal site comprises an entire nucleotide sequence set forth in SEQ ID NO: 3; and/or the promoter is located at 5′ end of the polynucleotide encoding CYP4V2.
3. A cell comprising the vector according to claim 1 .
4. A pharmaceutical composition comprising: a) the vector according to claim 1 , and b) a pharmaceutically acceptable adjuvant.
5. The pharmaceutical composition according to claim 4 , wherein the adjuvant includes stabilizer, excipient, diluent, solubilizer, surfactant, emulsifier, preservative, or any combination thereof.
6. A kit comprising: a) the vector according to claim 1 , and b) helper plasmids or helper viruses that provide helper functions for virus packaging.
7. A method for treating or alleviating Bietti's crystalline dystrophy (BCD), comprising administrating the vector according to claim 1 to a subject in need thereof, wherein the administration is subretinal injection.
8. The method according to claim 7 , wherein the dosing volume is from 50 μl to 300 μl, and/or the dosage is from 1×10 10 vg/eye to 1×10 12 vg/eye.
9. The method according to claim 7 , wherein the subject is human.